特比萘芬致患者味觉障碍的文献病例分析

Analysis of Cases in Literature on Dysgeusia in Patients Caused By Terbinafine

目的:分析特比萘芬致患者味觉障碍的临床特点,为临床特比萘芬的用药安全提供参考。方法:以“特比萘芬(terbinafine)”“兰美抒(lamisil)”“味觉(gustation/taste)”“味觉障碍(dysgeusia)”“味觉异常/味觉紊乱(taste disorder)”“味觉丧失(ageusia)”“味觉减退(hypogusia)”为关键词,在中国知网、万方数据库、重庆维普、PubMed、Embase等国内外数据库中检索建库至2023年9月的相关文献资料,采集纳入文献中患者的病例资料,分析特比萘芬致患者味觉障碍的临床特点。结果:在相关数据库中共检索到相关文献259篇,其中符合纳入条件的有15篇,涉及患者共22例(男6例,女16例);22例患者的诺氏评估显示,特比萘芬与味觉障碍的关联性为“很可能”的有21例(占95.45%),另1例结果为“可能”;22例患者中,味觉障碍的发生时间为用药后的1 d~12周(中位时间为8周),而其临床表现有味觉完全丧失(14例,占63.64%)和味觉部分丧失(8例,占36.36%);经处置,有15例患者味觉完全恢复,有4例未完全恢复,有2例则未恢复,另有1例结果不详。结论:临床患者在使用特比萘芬过程中可能出现味觉障碍的情况,且部分患者表现为不可逆性,故临床在使用特比萘芬时应做好患者的用药宣教,以便患者在此类药物不良反应出现的第一时间进行反馈和处置。

Objective:To analyze the clinical characteristics of dysgeusia in patients caused by terbinafine and provide reference for the clinical safe medication of terbinafine.Methods:The relevant documents and literatures from database establishment to September 2023 were searched from the domestic and foreign databases such as CNKI,Wanfang Database,Chongqing VIP,PubMed and Embase by using "terbinafine","lamisil","gustation/taste","dysgeusia","taste disorder","ageusia" and "hypogusia" as keywords.The case data of patients included in the literature were collected to analyze the clinical characteristics of dysgeusia in patients caused by terbinafine.Results:A total of 259 articles were searched from the relevant databases,of which,15 articles met the inclusion criteria,involving a total of 22 patients(6 males and 16 females);the Naranjo's assessment of 22 patients showed that there were 21 patients whose correlation between terbinafine and dysgeusia was "probable"(95.45%) and 1 patient whose correlation was "possible".Among the22 patients,the onset time of dysgeusia was 1 day to 12 weeks after medication(median time:8 weeks),and its clinical manifestations included complete loss of taste(14 patients,63.64%) and partial loss of taste(8 patients,36.36%);after management,15 patients recovered completely,4 patients did not recover completely,2 patients did not recover,and1 patient was unknown.Conclusion:Clinically,patients may develop dysgeusia during the use of terbinafine and some patients show irreversible symptoms.Therefore,patients shall receive propaganda and education about medication when using terbinafine in clinical settings,so that such adverse drug reactions can be fed back and managed as quickly as possible once occurring in patients.